Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆÄ³ªÁø     (Date : 2011-08-26 18:31:16)
Á¦¸ñ [³í¹®] [Microarray]Peptide nucleic acid-based (PNA) array for the antigenic discrimination of canine parvovirus
³»¿ë

Research in Veterinary Science 2011
DOI : 10.1016/j.rvsc.2011.06.003


Peptide nucleic acid-based (PNA) array for the antigenic discrimination of canine parvovirus

Dong-Jun An, Wooseog Jeong, Hye-Young Jeoung, Myoung-Heon Lee,
Jee-Yong Park, Ji-Ae Lim, Bong-Kyun Park

Abstract

A novel peptide nucleic acid (PNA)-based array was developed for use in ante-mortem antigenic typing discrimination in dogs with canine parvovirus (CPV). Cyclic benzothiazole-2-sulfonyl PNA monomers were synthesized that recognized GTA (CPV-2) and TAT (CPV-2a, -2b and -2c) at the nt 913-915 positions, and AAT (CPV-2 and CPV-2a), GAT (CPV-2b), and GAA (CPV-2c) at the nt 1276-1278 positions of the VP2 gene. The detection limits for aa 305 and aa 426 of the VP2 proteins belonging to the four CPV antigenic types were determined optically to be 40-2000 DNA copies, and the optimal cut-off fluorescence signaling value was fixed at 5000. The PNA array described here was developed from 135 field dog fecal specimens and had 89.8% (62/69) sensitivity and 90.4% (66/73) specificity compared with a real-time PCR using the TaqMan assay, a gold standard method. This CPV PNA array could be used together with MGB probe assays as an attractive novel tool for ante-mortem antigenic typing discrimination.

Keywords : CPV, PNA, MGB probe


 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆÄ³ªÁø 32701
   48           [³í¹®] [2015]IDH Mutation Analys.. ÆÄ³ªÁø 65535
   47           [³í¹®] [2015]Low frequency of KR.. ÆÄ³ªÁø 44046
   46           [³í¹®] [2015]Simultaneous genoty.. ÆÄ³ªÁø 6643
   45           [³í¹®] [2014]Simultaneous diagno.. ÆÄ³ªÁø 26440
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆÄ³ªÁø 13783
   43           [³í¹®] [2013]Detection of EGFR m.. ÆÄ³ªÁø 1521
   42           [³í¹®] [2013]Detection and compa.. ÆÄ³ªÁø 6178
   41           [³í¹®] [2013]Detection of BRAF V.. ÆÄ³ªÁø 6557
   40           [³í¹®] [2013]Comparison of Direc.. ÆÄ³ªÁø 34998
¢º           [³í¹®] [Microarray]Peptide nucle.. ÆÄ³ªÁø 20003
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆÄ³ªÁø 62687
   37           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆÄ³ªÁø 3825
   36           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆÄ³ªÁø 49717
   35           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆÄ³ªÁø 1592
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆÄ³ªÁø 26230
   33           [³í¹®] [ÆÄ³ªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆÄ³ªÁø 17595
   32           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆÄ³ªÁø 33418
   31           [³í¹®] [ÆÄ³ªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆÄ³ªÁø 4134
   30           [³í¹®] [ÆÄ³ªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆÄ³ªÁø 4366
 

< 1 2 3 >